https://ipharmag.com/article/solstice-oncology-225m-ctla4-porustobart iPharmag en 2026-09-09T23:20:29+00:00 Solstice Launches With $225M and a Faster-Clearing Take on an Old Cancer Target https://ipharmag.com/article/sandhoff-disease-gene-therapy-cat-model-lifespan iPharmag en 2026-09-09T23:20:29+00:00 A One-Time Gene Therapy Tripled Lifespan in a Fatal Childhood Disease Model https://ipharmag.com/article/h-pylori-colorectal-cancer-evidence iPharmag en 2026-09-09T23:20:29+00:00 Does a Common Stomach Bug Raise Colon Cancer Risk? The Evidence Is Building — and Messy https://ipharmag.com/article/astrazeneca-tozorakimab-il33-copd-mucus-plugs iPharmag en 2026-09-09T23:20:29+00:00 AstraZeneca Drug Becomes First Biologic to Cut COPD ‘Mucus Plugs,’ Data Show https://ipharmag.com/article/arpa-h-advocate-ai-heart-failure-62m iPharmag en 2026-09-09T23:20:29+00:00 US Health Agency Bets $62M on FDA-Authorized AI That Would Treat Heart Failure https://ipharmag.com/article/semaglutide-bipolar-psychiatric-hospitalization-benefit iPharmag en 2026-09-09T04:28:04+00:00 Semaglutide Tied to Fewer Psychiatric Hospitalizations in People With Bipolar Disorder https://ipharmag.com/article/novartis-avidity-del-desiran-myotonic-dystrophy-fail iPharmag en 2026-09-09T04:28:04+00:00 Novartis Shares Slide After $12B Avidity Drug Fails Its Pivotal Trial https://ipharmag.com/article/global-cancer-cases-surge-67-percent-2050 iPharmag en 2026-09-09T04:28:04+00:00 Global Cancer Cases Could Jump 67% by 2050, Report Warns https://ipharmag.com/article/early-statin-use-lower-dementia-risk-diabetes iPharmag en 2026-09-09T04:28:04+00:00 Starting Statins Early After a Diabetes Diagnosis Tied to Lower Dementia Risk https://ipharmag.com/article/brainchild-bio-116m-pediatric-brain-cancer-car-t iPharmag en 2026-09-09T04:28:04+00:00 A Seattle Startup Raises $116M to Send CAR-T Cells Straight Into Children’s Brains https://ipharmag.com/article/novo-nordisk-ziltivekimab-halts-heart-trials iPharmag en 2026-09-08T05:06:11+00:00 Novo Nordisk Halts Two More Heart Trials of Its Anti-Inflammatory Drug https://ipharmag.com/article/gsk-hutchmed-attc-egfr-kras-cancer iPharmag en 2026-09-08T05:06:11+00:00 GSK Bets $110M on Hutchmed and a New Class of Dual-Target Cancer Drug https://ipharmag.com/article/eu-barcode-individual-dose-medicines iPharmag en 2026-09-08T05:06:11+00:00 Europe Weighs Putting a Barcode on Every Single Dose of Medicine https://ipharmag.com/article/atomvie-radiopharmaceutical-facility-ontario iPharmag en 2026-09-08T05:06:11+00:00 A $160M Ontario Plant Bets Big on Radioactive Cancer Drugs https://ipharmag.com/article/aptar-aceso-inhaled-cystic-fibrosis-act101 iPharmag en 2026-09-08T05:06:11+00:00 An Inhaled RNA Drug Aims to Fix Cystic Fibrosis a Step Earlier